Saguenay, Canada; Zug, Switzerland

Eder Therapeutics and xcube.bio have announced a strategic cooperation to facilitate the market entry and commercialization of biotech assets in Canada and Europe. The two companies will coordinate their offerings to biopharma innovators in their respective regions and leverage the numerous synergies that exist between the healthcare systems of Europe and Canada. The collaboration will specifically focus on product profiling, regulatory processes, Health Technology Assessment (HTA), and medical communication, and commercialization - ultimately benefiting patients and biopharma partners.

"Eder Therapeutics is thrilled to combine its unique depth in the Canadian market with the breadth of a European platform like xcube.bio. This partnership will enhance access to innovative treatments for Canadian patients, which is our ultimate goal," said Jared Rhines, CEO of Eder Therapeutics.

Pierre-Henri Belin, CEO of xcube.bio, stated," xcube.bio, a European market-entry specialist, has found a valued like-minded partner in Eder Therapeutics. We look forward to expanding this cooperation to accelerate patient access and provide added value to our biopharma partners."

An initial phase of expert cooperation will begin with Eder Therapeutics' investigational AAV gene therapy for Lipoprotein Lipase Deficiency.

—

About xcube.bio

“Too complex, too expensive, too uncertain” - that's the sentiment echoing in the minds of many executives about launching in Europe. xcube.bio is a market-entry specialist, changing the game for patients waiting for treatment. We partner with innovators through a unique combination of deep-tech capabilities, expertise and a transformative business model to deliver sustainable organizations and profitable revenue streams. xcube.bio maximize European value for high unmet need, niche oncology and rare diseases emerging biopharma.